spacer
home > ebr > winter 2003 > will demand exceed supply for biopharmaceutical manufacturing?
PUBLICATIONS
European Biopharmaceutical Review

Will Demand Exceed Supply for Biopharmaceutical Manufacturing?

Manufacturing capacities have increasingly become cause for much speculation; many biopharmaceutical market participants consider this to be a crucial issue which will make or break the industry's progression. Once a new drug is discovered and clinical trials are conducted and approved by the drug approval authorities, the actual task of manufacture for commercial application begins. Construction of manufacturing facilities is not an easy task and requires anywhere between three to five years with a typical investment of around US$500 million. In the current economic situation, where raising capital is a difficult undertaking, building biopharmaceutical manufacturing reactors is not easy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Raju Adhikari, Mbiochem, Dphil, Research Analyst at Frost and Sullivan, Europe

Raju Adhikari, Mbiochem, DPhil is a Research Analyst at Frost and Sullivan, Europe. Since joining Frost and Sullivan, Raju has been involved in the research, analysis and production of market studies in the biotechnology field. His experience in the biotechnology sector comes from three years spent working at Everest Biotechnology Ltd, an emerging antibody company. As Chief Scientific Officer, his role involved Product Management, Business Development, Quality Control and Marketing/PR. Raju graduated with a First Class Masters degree from the University of Oxford. He received his doctorate, also from the University of Oxford, in the field of Immunology and has published several papers in scientific journals.

spacer
Raju Adhikari
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

The Latest Innovations in HPAPI Manufacturing Technologies

SMi’s inaugural Highly Potent Active Pharmaceutical Ingredients USA Conference, will focus on the latest innovative manufacturing technologies with a special spotlight presentation on effective and safe containment solutions for biologics based HPAPIs, along with cleaning and cross contamination requirements.
More info >>

White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement